MSCs
MSCs is a pharmaceutical drug with 14 clinical trials. Currently 1 active trials ongoing. Historical success rate of 100.0%.
Success Metrics
Based on 2 completed trials
Phase Distribution
Phase Distribution
6
Early Stage
7
Mid Stage
0
Late Stage
Highest Phase Reached
Phase 2Trial Status & Enrollment
100.0%
2 of 2 finished
0.0%
0 ended early
1
trials recruiting
14
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Study of Mesenchymal Autologous Stem Cells as Regenerative Treatment for Multiple Sclerosis
Autologous Stem Cell Therapy in Patients With Multiple System Atrophy
Mesenchymal Stem Cells for Chronic Kidney Diseases
Mesenchymal Stem Cell Treatment for Pneumonia Patients Infected With COVID-19
MSC for Severe aGVHD
Clinical Trials (14)
Study of Mesenchymal Autologous Stem Cells as Regenerative Treatment for Multiple Sclerosis
Autologous Stem Cell Therapy in Patients With Multiple System Atrophy
Mesenchymal Stem Cells for Chronic Kidney Diseases
Mesenchymal Stem Cell Treatment for Pneumonia Patients Infected With COVID-19
MSC for Severe aGVHD
Role of Stem Cells, Platelet Rich Plasma in Treatment of Scars
MSC for Treatment of Interstitial Lung Disease After Allo-HSCT
Mesenchymal Stromal Cell Derivatives in the Treatment of Chronic Diabetic Foot Ulcers Type 1 and 2
MSC Administration for the Management of Type 1 Diabetic Patients
MSCs Source of Sweat Gland Cells of Large Area Skin Injury Patients Transplant of the Wound
MSC for Treatment of CMV Infection
MSCs With or Without Peripheral Blood Stem Cell for Treatment of Poor Graft Function and Delayed Platelet Engraftment
MSCs Combined With CD25 Monoclonal Antibody and Calcineurin Inhibitors for Treatment of Steroid-resistant aGVHD
Peripheral Blood Stem Cell Combined With Mesenchymal Stem Cells for Treatment of Poor Graft Function
All 14 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 14